-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Day One Biopharmaceutical, Lowers Price Target to $27

Benzinga·03/25/2025 15:38:11
Listen to the news
Goldman Sachs analyst Andrea Tan maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Buy and lowers the price target from $39 to $27.